Immunotherapy is one of the most important breakthroughs in cancer treatment, especially immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) and PD ligand 1 (PD-L1), which significantly prolonged overall survival (OS) and possessed superior safety profile in patients with cancer compared with standard therapies across a wide range of tumor types.
1,2 With the increasing studies in immunotherapy, differences between the clinical performance of anti–PD-1 and anti–PD-L1 started to be reported. For example, recent findings from the KEYNOTE-426 study demonstrated significant OS improvement with the combination of anti–PD-1 (pembrolizumab) plus axitinib vs sunitinib in previously untreated patients with advanced renal cell carcinoma (RCC)
3; however, anti–PD-L1 (avelumab) plus axitinib failed to demonstrate OS superiority over sunitinib in the same settings.
4 In addition, anti–PD-1 (pembrolizumab) plus carboplatin and nab-paclitaxel has been approved by the US Food and Drug Administration for first-line treatment of metastatic, squamous non–small cell lung cancer (NSCLC) based on the positive results from KEYNOTE-407,
5 while anti–PD-L1 (atezolizumab) plus carboplatin and nab-paclitaxel failed to show an OS benefit compared with chemotherapy in squamous NSCLC in IMpower131.
6,7 Such disparities have attracted widespread attention by clinicians, and there is a need to better understand the similarities and differences between anti–PD-1 and anti–PD-L1 for the ultimate benefit of patients with cancer.